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Discovering and Assessing Fields of Expertise in 
Nanomedicine: A Patent Co-Citation Network 
Perspective 
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ABSTRACT 
Discovering and assessing fields of expertise in emerging technologies from patent data is not 
straightforward. First, patent classification in an emerging technology being far from complete, the definitions 
of the various applications of its inventions are embedded within communities of practice. Because patents 
must contain full record of prior art, co-citation networks can, in theory, be used to identify and delineate the 
inventive effort of these communities of practice. However, the use patent citations for the purpose of 
measuring technological relatedness is not obvious because they can be added by examiners. Second, the 
assessment of the development stage of emerging industries has been mostly done through simple patent 
counts. Because patents are not all valuable, a better way of evaluating an industry’s stage of development 
would be to use multiple patent quality metrics as well as economic activity agglomeration indicators. The 
purpose of this article is to validate the use of 1) patent citations as indicators of technological relatedness, 
and 2) multiple indicators for assessing an industry’s development stage. Greedy modularity optimization of 
the ‘Canadian-made’ nanotechnology patent co-citation network shows that patent citations can effectively be 
used as indicators of technological relatedness. Furthermore, the use of multiple patent quality and economic 
agglomeration indicators offers better assessment and forecasting potential than simple patent counts. 
Keywords: Knowledge discovery, nanomedicine, self-organization, trend analysis, citation network analysis, 
S-curve 
1 Introduction 
Bibliometric data can be used to assess and forecast technological progress (Martin 1995; Watts and Porter 
1997; Daim et al. 2006). Among the many purposes it serves, bibliometric data can be used for trend analysis. 
Such analysis can show how a given field has evolved over time, help to forecast future technological 
directions, identify promising research areas and support new product development decisions. Trend analysis 
often consists in fitting the progress and growth of bibliometric data with technology diffusion models. In 
this regard, cumulative technology development is generally recognized to follow an S-shaped curve over time 
(Andersen 1999; Daim et al. 2006). In this model, development in a discipline grows exponentially until an 
inherent upper limit is reached. At this point, growth slows down and eventually saturates. These two phases 
of growth and saturation are representative of technological opportunities in a given disciplines (Andersen 
1999). An emerging discipline initially offers great opportunities and thus exhibits exponential growth in 
terms of bibliometric indicators. As novelties accumulate and occupy the technological landscape, smaller 
areas of opportunities are left available which leads into a slowing down of bibliometric indicators. This 
process is self-propagated and results from the collective effort of opportunity seeking innovators.  
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Within the available bibliometric data sources, patents have been extensively used to measure innovative 
activity (Pavitt 1985; Narin 1994; Narin and Hamilton 1996). Because patents must be novel, non-obvious 
and useful, they are indicators of technological progress and change (Acs and Audretch 1989; Archibugi and 
Pianta 1996). Moreover, the accumulation of patent stocks in a discipline takes place because of interactions 
between scientists, inventors and entrepreneurs. Changes in patenting activity can therefore be used to assess 
the development stage of various technological sectors (Andersen 1999). Naturally, the analysis of trends and 
patterns of patenting activity in emerging industries is a popular subject of research. Among these, 
nanotechnology has been experiencing rapid development which leaves traces through growth in research 
grants, the publication of academic papers and the granting of patents (Hullmann 2006; Kostoff et al. 2007; 
Alencar et al. 2007; Takeda et al. 2009; Porter et al. 2008; Dang et al. 2010; Grieneisen 2010). Numerous 
countries have put in place initiatives to foster their scientific and technological capabilities in this field 
(Alencar et al. 2007; Li et al. 2009). Nanotechnology results from the combination and integration of scientific 
and technological concepts from different fields such as physics, chemistry, biology, material sciences, 
mechanics and electronics. In this regard, it can also be viewed as a multidisciplinary field (Meyer and Persson 
1998). This intrinsic nature of nanotechnology makes its definition, the identification of its field as well as the 
delineation of its boundaries difficult to achieve. 
Within all applications of nanotechnology, nanomedicine is of particular interest, because it may partly be the 
result of nanotechnology and biotechnology convergence. Freitas (2005) for instance defines the concept as 
the medical application of nanotechnology. According to the European Science Foundation, this field aims at 
“ensuring the comprehensive monitoring, control, construction, repair, defense and improvement of all 
human biological systems, working from the molecular level using engineered devices and nanostructures, 
ultimately to achieve medical benefit” (ESF 2005, p. 8). It has various application fields in drug delivery, 
cancer treatment, surgery and medical imaging to name a few. Given the importance of these various 
applications to human healthcare, nanomedicine is one of the most promising fields of nanotechnology.  
So far, the bibliometric literature has been mainly concerned with the study of trends in nanotechnology as a 
whole. Although a few studies have concentrated on sub-disciplines within nanotechnology, nanomedicine 
has not yet been tackled in a great deal of details. Two quantitative studies can be associated with 
nanobiosciences.  The first is by Pei and Porter (2011) who use the relevant WOS subject categories to extract 
nanobioscience articles from a nano-dataset. In a similar fashion, Li et al. (2007a) identify patent classes that 
can be potentially associated with nanomedicine, but these classes are not reserved for nanomedicine and 
could also contain patents for the nanobiotechnology sector. Furthermore, patent classes do not reveal much 
detail about the nature of applications that are developed in an emerging field. By definition, emergent 
disciplines are continuously growing and are redefined through what the communities of practice (Wenger 1999) 
believe are promising applications or technological paths. This makes it difficult for observers such as those 
within the USPTO in setting up standard classification of patents in nanotechnology. Of course, the USPTO 
has reserved class 977 to nanotechnology patents, but this class only contains a small proportion of 
nanotechnology patents. The lexical query of Porter et al. (2008) returns nearly 50,000 patents between 1990 
and 2005, while the USPTO currently (as of June 2012) classifies only 4,193 patents in class 977 for the same 
period.  
The second quantitative study is by Takeda et al. (2009) which focused on nanobioscience articles as the unit 
of analysis and uses a very general lexical query (‘bio*’ and ‘nano*’). The authors use greedy modularity 
optimization to discover major fields of scientific research in nanobiosciences from scientific paper citation 
networks. They find that the discipline is divided into four fields: nanostructures, drug delivery, bio-imaging 
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and biosensors. For the period 1990 to 2005, theses field all show exponential growth indicating that 
nanobiosciences have not yet reached the inflection point associated with the abovementioned S-shaped 
growth curve. While the adoption of such unsupervised learning techniques to the case of patents seems 
attractive, certain theoretical issues need first to be raised. Indeed, if one can easily conclude that paper 
citations can indicate knowledge flows, it is not so obvious in the case of patents, mainly due to the existence 
of examiner citations. As a result, the study of the commercial applications of nanomedicine are mostly 
qualitative in nature. In a study of the most promising application fields for nanomedicine (therapeutics, drug 
delivery, tissue reconstruction and imaging and diagnosis), Perkel (2004) states that nanomedicine 
development is still in its infancy as it will be decades before dominant firms that are equivalents to the 
“IBMs, Intels, or Microsofts of the world” emerge in this new sector.  
Another issue related to the use of patent data as progress indicators is in the sole reliance upon patenting 
activity trends for the assessment of emerging industries. Porter et al. (2008) show that nanotechnology patent 
production experienced three major leaps for the years 1998, 2001-2002 and 2005 at the international level. 
Dang et al. (2010) find similar results when looking at international patent applications. Fitting these trends 
against logistic curves could indicate that nanotechnology has yet to reach its inflection point where growth 
starts slowing down. However, this is not always true about nanotechnology sub-fields. In a study of 
nanotube field emission display patents between the years 1994 to 2007, Chang et al. (2010) show that the 
number of patent applications has slowed down after 2004. Meyer (1994) introduces the concept of bi-logistic 
growth. This model describes a system that contains two S-shaped curves: a first period of stagnation can be 
followed by new period of growth and stagnation manifested through two serial logistic curves. This second 
growth leap is due to environmental changes that lead to a new carrying capacity of the technology. From this 
perspective, curve fitting of simple patent counts against a logistic curve might miss the complex relationship 
that technological development has with other economic phenomena that could predict changes in the 
carrying capacity. 
Furthermore, although the use of patenting activity is attractive for industries in which commercial data is not 
yet easily available, their use for evaluating proximity to commercialization is not straightforward because 
patents are not all valuable as only a small percentage succeed in generating income (Allison et al. 2004; Moore 
2005). It should also be noted that patents are not always filed with the intention of building new products. 
For instance, firms can license patents for defensive or plain trolling purposes (Hall and Ziedonis 2001; Gallini 
2002; Moore 2005; Reitzig et al. 2007). Even though strategic patenting is less often employed for discrete 
products such as chemicals, pharmaceuticals and biotechnology applications (Cohen et al. 2000; Hall and 
Ziedonis 2001), it is customary enough to justify for the analysis of trends in cumulative patent stocks in 
tandem with other metrics to control for the variance in patent quality (Lanjouw and Schankeman 2004) and 
have a better understanding of the technological landscape. 
This article fulfills the need to answer the two abovementioned issues. Our first objective is to verify whether 
patent citations be used as a measure of technological relatedness. Our second objective is to verify if multiple 
patent metrics and economic indicators can offer better insight about the stage of development of an 
emerging industry. Our methodology consists in partitioning projected patent co-citation networks of the 
Canadian nanomedicine industry and to verify partition quality in order to validate the use of patent citations 
as indicators of technological relatedness. We then perform trends analysis on the top partitions, which 
represent leading Canadian fields of expertise in nanomedicine. The use of ultiple indicators will validate that 
they can contain useful information not conferred by simple patent counts. 
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The remainder of the article goes as follows: Section 2 presents some of the implementation issues regarding 
patent citation networks partitioning and our approach to test their validity ; Section 3 presents the 
conceptual framework used for assessing emerging fields of expertise; Section 4 describes the data used; 
Section 5 explains the methodology used; Section 6 presents the results of our analysis; and finally Section 7 
concludes. 
2 Discovering Know-How: Implementation Issues 
Given the difficulties of identifying the nature of technological development – and thus national competences 
– in an emerging discipline, the first objective of this article is to provide a method for characterizing the self-
organized nature of technological development in the Canadian nanomedicine community of practice. 
Inventive activity can be viewed as a complex dynamic system involving the collective effort of autonomous 
opportunity seeking agents (Fleming and Sorenson 2001). Another aspect of knowledge creation is that it is a 
path dependent process, where new knowledge is built on top of old knowledge (Rosenberg 1994). Thus, 
inventors evolve in a community which is constantly combining existing knowledge to create new ones. This 
search-and-combine effort results in a complex system where pieces of old knowledge and new knowledge 
are interlinked. This linkage does not follow a random pattern as ideas that solve common problems are 
linked to at a higher rate (Fleming 2001). This self-organized behavior leads to the formation of small-world 
and scale-free networks (Watts and Strogatz 1998; Barabasi and Albert 1999). In such settings, communities 
which exhibit dense inter-linkage of ideas emerge. Finding these communities can thus indicate the kind of 
knowledge that practicians in a technological discipline are producing. Since our intention is not to study the 
progress of disciplines that fall within predefined classes, unsupervised learning methods for knowledge 
discovery seem to be a natural choice for this purpose.  
Because patents must contain references to all relevant prior art, patent citations can, theoretically, be used to 
build a network in which communities represent major fields of technological development. Finding such 
communities can come down to finding areas of high inter-citation between patents. Among unsupervised 
learning methods, cluster analysis can be performed on network data in order to identify areas, in which case 
it can be viewed as a way to achieve community detection in graphs (Girvan and Newman 2002). Cluster quality 
functions – such as the network modularity – can be used to detect an optimal number of communities 
(Newman and Girvan 2004). Modularity computes the degree to which vertices inside a community are 
interconnected compared to the probability of them being interconnected in a random graph of similar 
density.  
Community detection algorithms have been used by scientometricians to map scientific papers and identify 
scientific disciplines (Wallace et al. 2009; Takeda et al. 2009). These studies rely on the principle that co-
citations can be viewed as a measure of similarity between documents (Small 1973). Other studies have 
extended this principle to patent citations in order to group technologically similar patents together 
(Breitzman & Mogee 2002; Breitzman 2005; Li et al. 2007b; Barirani et al. 2011). Thus, these studies have 
extended the principle used for papers to patents. It is worthwhile to mention that this assumption cannot be 
readily made without considering the difference between patent and paper citations. In fact, co-citation 
classification of scientific articles finds justification in the fact that citations in scientific publications can be 
easily associated with knowledge flows (Meyer 2000b; Leydesdorff 2008). However, the interpretation of 
patent citations must be put in context due to the fact that 1) a large proportion are added by examiners, and 
2) that applicants can add them for strategic reasons (Sampat 2005). Meyer (2000a) also points out that time 
constraints can also lead to examiners adding citation than are only remotely linked to the filed patent. 
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Therefore, patent citations do not automatically indicate knowledge flows from cited to citing patent and thus 
the argument used for scientific publications cannot be automatically used for patents. However, one can 
interpret citations as indicators of technological relatedness due to the fact that they result from and are 
strongly related to USPTO’s patent classification process (Lerner, 1994). It is therefore possible to interpret 
patent citations as a measure of how close two inventions are from a technological point of view rather than 
as a measure of knowledge flows from one patent applicant to another. The second research question 
covered in the present study concerns the validity of this hypothesis. Indeed, even if our conception of 
technological relatedness is not in any way synonymous to that of knowledge flow, it is worthwhile to verify 
whether examiner citations can become obstacles to the soundness of citation-based community detection 
techniques. In other words, we are interested in verifying the degree with which co-citations result from a 
controlled process that can indicate technological relatedness between patents. 
Numerous indicators can be used to test the above hypothesis. The more citations are away from being the 
result of a controlled process and the more they result in arbitrary assignments (due to lack of time from 
examiners for instance), the more patent citation networks will resemble random graphs. On the other hand, 
if citation assignment process is relatively well defined, our network should exhibit small-world and scale-free 
characteristics common to real-world networks. 
Furthermore, once community detection algorithm is applied to the patent citation network, assignee 
information can also contribute in testing our hypothesis. Since organizations are more likely to specialize in 
one or a few technological fields, their patents should not be uniformly distributed within partitions. Rather, 
partitions should be dominated by a few firms. It should also be noted that the domination of all partitions by 
one single organization could also mean that the partitioning procedure was not effective in grouping similar 
technologies developed by different organizations. This could mean that modularity optimization of patent 
citation network does nothing more than grouping together patents from the same organizations. We thus 
expect partitions to be represented by more than one assignee. Of course, it is possible that one or a few 
partitions be dominated by one firm, as monopolies do exist in various industries. 
3 Assessing National Capabilities: Conceptual Framework 
As we have observed earlier, patents are not always accurate in indicating progress from a commercial point 
of view. Other patent quality indicators can be used in tandem with patent counts in order to assess the 
progress of an industry. Among these metrics, patent claims are generally recognized as indicators of patent 
value since they define the patent’s scope (Merges and Nelson 1990). Indeed, the broader a patent’s scope, 
the larger the number of competing patent that infringe upon it. As a result, patent applicants are willing to 
have as many claims as possible, while examiners must make sure than all claims are justified and that the 
patent’s scope is correctly defined (Meyer 2000a). It should however be noted that more claims do not 
automatically translate into legal protection for patent holders. Indeed, the USPTO and courts often have 
contradictory views about the interpretation of patent claims (Merges and Nelson 1990). The USPTO follows 
the doctrine of disclosure, meaning that the applicant is granted a patent if it provides adequate disclosure of 
the invention. Courts, however, follow the enablement principle in which infringement occurs when an 
equivalent use of claims is made by a competing product. Nevertheless, studies find statistically significant 
relationship between the number of claims and patent value (Tong and Frame 1994; Allison et al. 2004). 
Patent citations are also signals for patent quality. With regards to the examiner citation issue, it should 
however be noted that they are not strictly synonymous with noise. For instance, Alcacer and Gittelman 
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(2006) find that examiners add a larger proportion of self-citations than the inventors themselves. Hedge and 
Sampat (2009) find that examiner citations are more significantly associated with patent value. Without being 
an indication for knowledge flow, examiners’ involvement in the prior art citation process can also be viewed 
as a smoothing process that insures a thorough citation of prior art. This is generally more recognized for the 
USPTO patenting system (Meyer, 2000a). Other studies find that a number of characteristics such as firm size 
and the industrial sector have an impact on the proportion of examiner citations (Alcacer and Gittelman 
2006; Alcacer et al. 2009; Azagra-Caro et al. 2011). In the case of discrete technologies, a larger proportion of 
citations originate from applicants (Alcacer et al. 2009). Sampat (2005) also points out that examiner-added 
citations represent a smaller proportion of citations in new fields where the majority of prior art resides 
outside the USPTO patents. Thus, following aggregate citation trends within a discipline that is homogenous 
in terms of firm size, technology type (discrete vs. complex) and industry characteristics allows to control for 
variations in the examiner/applicant citations proportions and lead to robust conclusions about the progress 
of the said discipline.  
It is also worthwhile to distinguish between different interpretations that can be made from forward and 
backward citations. Forward citations to a patent are generally recognized as indicators of the patent’s 
economic value but also of its technological importance (Albert et al. 1991; Trajtenberg 1990; Archibugi and 
Pianta 1996; Hall et al. 2005; Abraham and Moitra 2001). The number of backward citations is another 
indicator of patent quality. Allison et al. (2004) suggest that citing more prior art will lead to stronger patents 
in the face of litigation. The number of backward citations to patents can also be used to assess the novelty of 
a technology (Carpenter et al. 1981). New technologies are often sourced in science and have little links to 
existing patents. As solutions to technological problems are found, future inventions can rely on them, which 
lead to a rise in the number of backward citations to patents. Patents in emerging technologies are therefore 
expected to experience an increase in the number of backward citations to other patents as the sector 
matures.  
Non-patent references (NPRs) have also been considered in the literature. These are references made to other 
prior art such as books, journal articles or standards. Callaert et al. (2006) find that most NPRs are references 
to scientific journals. Discrete technologies have a higher proportion of NPRs than complex technologies or 
processes. NPRs are also less likely to be added by examiners, which can be linked to a propensity by 
examiners to concentrate on citing USPTO patents (Sampat 2005). Thus, NPR trends within a technological 
field can indicate the progress of that discipline’s need upon basic science. Meyer (2000b) also points out that 
science-technology linkage is not a linear process and that the presence of NPRs does not imply that cited 
literature was used during the invention process. Instead, science-technology linkage involves the circular 
interaction of technological exploitation and scientific exploration. The process of scientific exploration can 
be viewed as a way to reach new insights that can lead to new inventions which, in turn, can be further 
improved and optimized during the technological exploitation process. Allison et al. (2004) find that the 
number of NPRs is positively linked to litigation possibilities. Given the high legal expenses generated by 
litigation processes, NPRs can be linked to patent value.  
Although patents are not all of equal value, patent protection increases the chance of an invention reaching 
the commercialization stage (Webster and Jensen 2011). Furthermore, commercialization possibilities increase 
with patent strength (Dechenaux et al. 2008). It should be noted that technology commercialization is not 
limited to the production and distribution of new products. Technology transfer mechanisms such as patent 
licensing and buyouts are other channels for monetizing inventions. This principle holds for public 
institutions, for which licensing is a source of monetizing publicly funded research in North America. Even 
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patent trolling can be viewed as a form of market intermediation and legitimate income seeking in the 
knowledge economy (McDonough III 2006). Therefore, for a given technological sector, increases in metrics 
such as the patent count, forward citations, backward citations, NPRs and claims can be viewed as indicators 
of closeness to the commercialization stages (Breitzman and Mogee 2002; Nerkar and Shane 2007; Chang and 
Breitzman 2009; Cheng et al. 2010). Furthermore, it would be interesting to study whether growth or 
slowdown in the overall number of patents granted is accompanied by similar growths or slowdowns in the 
number of backward citations and NPRs. This will allow for a better understanding of the intertwined 
science-technology link in nanomedicine (Meyer 2000b). 
The interpretation of trends in patent metrics must however be nuanced given the complex regulatory 
framework in which nanomedicine evolves. Indeed, the use of nanomedicine is still a socially controversial 
subject. Since technological progress is to a certain degree independent from social and legal concerns, 
growth in trends do not automatically indicate commercialization opportunities. Furthermore, the 
conclusions taken based on these metrics are not an absolute indication of closeness to income generation. 
Rather, they must be used to indicate how one discipline is positioned compared to another.  
Compiling information about patent applicants such as inventors and assignees can provide information 
about dominant firms, technological proximity between firms (which can lead to partnerships as well as 
merger and acquisition possibilities) and the location of communities of practice (Breitzman and Mogee 2002; 
Breitzman 2005; Pei and Porter 2011). Concerning the geographical dimension, inventive activity often 
clusters in a region because of supply-side and demand-side benefits associated with geographical proximity 
(Krugman 1991; Porter 1998). Among these benefits, the agglomeration of innovators in a region leads to 
knowledge spillovers (Jaffe et al. 1993; Audretsch and Feldman 1996; Maskell and Malmberg 1999). Patenting 
activity involves high levels of technological experimenting, part of which is tacit knowledge and thus reflects 
the localized learning that occurs in a region (Anderson 1999). The clustering of inventive activity in a 
geographical region can therefore be a sign of increasing returns for that region but also of the formation of 
an industry (Zucker et al. 1998).  
The centrality of the position that public institutions play within the knowledge network of an industry can 
also be used as an indication of the industry’s stage of development. Owen-Smith and Powell (2004) show 
that universities played a central gatekeeping role in the early days of the biotechnology cluster in Boston. As 
the industry matures, large corporations become the central players in the network. Based on this parallel, we 
believe that public institutions, and especially universities, play a similar central role in the Canadian 
nanomedicine sector which is expected to be in its early days. It could also be interesting to put our findings 
in perspective with studies concerned with nanotechnology as a whole. In this regard, literature points to 
mixed results. For instance, in results by Alencar et al. (2007, Table 2), only 2 public institutions appear in the 
top 5 assignee list. Li et al. (2007c, Table 6) show that public institutions represent 1 out of 5 top patent 
assignees in the USPTO. 
4 Data 
To fulfill our research objectives we analyze a sample of Canadian nanotechnology patents that are registered 
at the USPTO. These patents where obtained by performing a lexical extraction on patents containing 
nanotechnology related keywords. These keywords were obtained from a set of bibliographic studies (Alencar 
et al. 2007; Fitzgibbons and McNiven 2006; Mogoutov and Kahane 2007; Porter et al. 2008; Schmoch et al. 
2003; Zitt and Bassecoulard 2006). These studies, altogether, use more than 596 distinct keywords in their 
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definition of nanotechnology with only 40 keywords being used in more than one study. As these figures 
show, experts do not agree on a unified lexical query delineating nanotechnology discipline (Hullmann and 
Meyer 2003; Takeda et al. 2009; Maghrebi et al. 2011). However, keywords that are used in more than one 
study can be viewed as common agreement on what constitutes core nanotechnology keywords. In fact, 
Huang et al. (2011) show that the use of these common keywords leads to lexical queries that result in similar 
bibliographical extractions. For data extraction purposes, we choose this set of keywords to form a lexical 
query that is run on the USPTO database. The selection of the USPTO is motivated by the close commercial 
partnership between the US and Canada.  The US economy is by far the largest marketplace for high 
technology. It thus attracts the highest level of competition and is therefore a clear indication of technological 
capabilities for those who are able to innovate in it. Li et al. (2007c) also show that Canadian assignees prefer 
filing patents in the US rather than the EPO. All granted patents that contain one of these keywords in all 
their fields and that have been granted to Canadian firms or for which one of the inventors resides in Canada 
are retrieved from the database. The sample is also expanded by patents classified under USPTO class 977 
which has been reserved for nanotechnology. It should be noted that the USPTO currently assigns 156 
Canadian patents to class 977, 12 of which are missed by the lexical query. We thus believe that our sample is 
a good representation of Canadian nanotechnology patents. 
Table 1 shows the core keywords for which at least one Canadian patent was extracted from the USPTO 
database. For each patent, data about the title, abstract, grant date, number of claims, references, backward 
and forward citations, as well as the name, city and country of inventors and firms are extracted. After 
cleaning for duplicates and missing data, our sample contains 6,288 unique Canadian nanotechnology patents 
obtained from 1990 to 2009.  
Table 1: Keywords used in lexical patent extraction. 
Term Patents Term Patents Term Patents 
atom* force microscop* 88 molecular beam epitaxy 77 polymer protein 38 
biosensor 231 molecular engineering 44 polymer rna 3 
drug carrier 182 molecular motor 5 polymer virus 2 
drug delivery 972 molecular switch 22 quantum 1077 
gene delivery 239 molecular template 3 scanning prob* 30 
gene therapy 906 nano* (excluding nano2, 
nano3, nano4, nano5, 
nano*aryote*, nanoalga*, 
nanobacteri*, 
nanofauna*, nanoflagel*, 
nanoheterotroph*, 
nanoliter*, nanomeli*, 
nanophtalm*, 
nanophyto*, 
nanoprotist*, 
nanosecond*, plankton*) 
3188 scanning probe 
microscop* 
16 
immobilized dna 22 nems 5 self assem* 219 
immobilized 
polynucleotide 
1 photonic* 868 single electron* 75 
immobilized primer 1 polymer composite* 261 supramolecular 12 
 
 
9 
chemistry 
immobilized template 2 polymer dna 9 transmission electron 
microscopy 
198 
mesoporous material* 20 polymer enzyme 15 tunnel* microscop* 2 
molecular beacon 13 polymer polynucleotide 3   
5 Methodology 
We build the backward citation network obtained from the extracted Canadian nanotechnology patent data. 
Backward citations have the advantage of being fixed over time as opposed to forward citations. Therefore, 
using both backward and forward citations to cluster patents will create a bias towards clustering older 
patents together. Our technology network is a bipartite graph, i.e. a graph in which vertices are divided in two 
classes 𝑝 and 𝑞 where edges only connect vertices of class 𝑝 to vertices of class	𝑞. In our case, 𝑝	is the set of 
Canadian nanotechnology patents and 𝑞 is the set of patents that are cited by them. From this bipartite graph, 
we build its weighted projected graph which is a network where nodes are Canadian patents and where edges’ 
weights represent the number of patents that Canadian patents have in common. The projected Canadian 
nanotechnology backward citation network is then partitioned by using the greedy modularity optimization 
algorithm by Clauset et al. (2004). Subsequently, we summarize relevant information regarding the partitions 
found in the previous step by adopting the method proposed by Barirani et al. (2011). For each partition, we 
merge the titles and abstracts of the patents that are assigned to them. Each partition therefore represents a 
document for which 3-grams will be built after removing common stopwords. Then, tf-idf term weighting will 
be computed for each document, each of the 3-grams being treated as a term. We will then select the top 10 
3-grams for each partition. Summarization will also be complemented by information regarding patent 
assignees. Once 3-grams and top assignees are identified for each partition, we perform an expert search in 
order to identify partitions that are related to nanomedicine. Here, we use our initial definition of 
nanomedicine, i.e. the application of nanotechnology for medical purposes. Assignee information will help 
experts in correctly identifying partitions that contain nanomedicine patents as it could be confusing to rely 
solely on 3-grams for the distinction of nanomedicine partitions in the case of nano-devices or nano-
molecules. Partitions for which top keywords and assignees can be associated with health sciences will be 
selected as nanomedicine partitions. Nanobiotechnology applications (such as plants, hybrid seeds, water 
treatment applications, etc.) are thus not retained as nanomedicine patents. This step is finalized by 
performing a second modularity optimization partitioning of the ‘nanomedicine-only’ projected network. This 
step is motivated by the resolution limitation associated with modularity optimization (Fortunato 2010). 
Indeed, modularity will give partitions that are sized similar to the network’s scale. Since the initial 
partitioning is performed on a larger graph representing nanotechnology as a whole, a second partitioning of 
the smaller nanomedicine network will result in a resolution obtained at a smaller scale. 
A few words must be said with regarding expert search. First, this procedure is only practical when dealing 
with datasets representing a narrow technological field and where a relatively small number of clusters must 
be identified. Patent titles and abstracts are indeed very technical in nature and difficult to understand for 
those who are outside the field of expertise. Applying this method to patents coming from a broad set of 
fields is not effective as it becomes difficult for experts to discriminate between clusters that use similar terms 
but applied in different technological sectors. Nevertheless, expert searches are common in the scientometrics 
literature and can constitute a reliable method in our case due to the fact that we deal with a small number of 
patents that will be assigned to a relatively small number of clusters. Second, one can raise the question as to 
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why expert search is not introduced earlier in the process so that non-nanomedicine patents are removed 
earlier from the initial sample. The main justification for using our method is that manual classification of 
patents is a costly process that is not free of error. On the other hand, the task of distinguishing between 
different domains of application is already performed once by USPTO examiners and this effort leaves traces 
in the form of patent classification and citations. Our method takes advantage of this available information 
for grouping technologically similar patents and minimizing subjective intervention to a smaller number of 
items that are clusters. Of course, citation-based clustering is not a perfect science and it can lead to the 
arbitrary assignment of patents that are in between two disciplines. However, given the expected scale-free 
and small-world characteristics of citation networks, these central patents will constitute a small proportion of 
patents and thus have negligible impact on the aggregate results. 
The next steps will consist in assessing the nanomedicine industry by analyzing patent metric trends at 
different levels. The analysis is performed at field of expertise, city and organization levels. Visualization of 
technological and organizational maps is also performed following Harel and Koren (2002)’s force directed 
placement technique. At the field of expertise level, we consider patent counts as well as the average number 
of claims and citations. Based on trends in these metrics, we will identify fields that are closer to maturity and 
commercialization compared to the others. A technological map will indicate the level of technological 
relatedness between fields and the degree of interdisciplinarity of the nanomedicine industry. At city level, we 
identify Canadian metropolitan areas in which the largest communities of nanomedicine inventors reside. We 
then compare the ratios of nanomedicine inventors to the number of inhabitants and identify areas that have 
a larger proportion of their population working in the nanomedicine industry. These ratios will be used as 
indicators of the clustering of innovative activities in a geographical region. For each city, we compute the 
degree of specialization in the fields of expertise. This allows us to compare cities that are specialized in a few 
fields versus those that are diversified in many of them. At the organizational level, we will compute top 
assignees in our Canadian nanomedicine patent sample. This will indicate the degree of competitiveness and 
the role played by public institution in total patent production. The organizational map will also show the 
network position filled by public institutions. Again, mapping is performed through co-citation analysis, based 
on our assumption that citations are an indication of technological relatedness. 
6 Results 
6.1 Discovering expertise 
Our initial sample of 6,288 Canadian nanotechnology patents cite 50,504 distinct patents which lead to a 
citation network composed of 56,454 vertices and 100,467 edges. The main connected component contains 
3,876 Canadian patents, 33,674 distinct cited patents and a network containing 78,234 edges. The main 
component is therefore more than half the size of the initial set of Canadian patents. Furthermore, it contains 
more than 75% of the edges in the initial network. Taking into account that the initial network contains 1,522 
disconnected components, which are mostly singletons (see Table 2), we select the main component as a 
representation of the core Canadian nanotechnology landscape. It should also be noted that the selection of 
the largest connected component is imposed by our choice of backward citations as measures of 
technological similarity as well as modularity optimization for graph partitioning. Since modularity 
optimization consists in minimizing inter-partition links, a modularity optimization algorithm fed with a 
disconnected graph will find that the graph’s connected components represent the best modularity, which is 
equivalent to finding the number of disconnected components. Furthermore, force directed layout requires 
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edges between vertices in order to position vertices on a two-dimensional map. The absence of edges 
between disconnected components means that they cannot be positioned one relative to another.  
Figure 1 shows the graph obtained by projecting the main connected component. As we can see, this is a 
complex network with many areas of dense inter-citation. The maximum and average geodesic distances in the 
connected component are equal to 24 and 5.96 respectively. This network can therefore be classified as a 
small-world. The network also exhibits scale-free characteristics with skewed distribution of centrality among 
patents (see Figure 2). So far, these characteristics seem to indicate that the use of co-citations for measuring 
technological similarity between patents is sound. Furthermore, these characteristics make our citation 
network a good candidate for modularity-based graph partitioning techniques. 
Table 2: Number of components of the same size. There is one large component with 3,856 Canadian patents, while 1,334 
components are singleton Canadian patents.  
Component size 
(number of 
Canadian patents) 
Number of 
components 
3876 1 
13 1 
10 3 
9 1 
8 2 
7 3 
6 12 
5 11 
4 22 
3 57 
2 190 
1 1219 
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Figure 1: Projected graph of the Canadian nanotechnology patent citation network. Separation lines represent manual 
(somehow arbitrary) partitioning of the graph. 
Figure 2: Network’s degree distribution follows a power law: very few patents have many connections with other patents 
with most patents having few connections with other patents. The graph shows that the network exhibits scale-free 
characteristics. 
The execution of greedy modularity optimization leads to the discovery of 62 fields of expertise for the 
Canadian nanotechnology sector. The best modularity found by the algorithm is 0.8997. Given the theoretical 
maximum modularity value of 1, partitioning found by the Clauset et al. (2004) algorithm is excellent given the 
nature of nanotechnology industry. Because of multidisciplinarity, different fields within nanotechnology 
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might be commonly linked through basic technologies. Also, such fields will have a higher proportion of in-
between patents, which will increase inter-partition linkage. In such cases, good partitioning of the network 
will still lead to relatively low modularity. The emerging nature of nanotechnology also contributes to 
increasing the number of common sources between different fields of expertise. This is due to the fact that a 
new technological sector must initially source itself in a few basic technologies that contribute to the 
propinquity of seemingly distant fields. 
We further evaluate the partitioning of the greedy algorithm by analyzing the top keywords and assignees for 
the 4 largest fields of expertise in nanotechnology. The results are shown in Table 3. We can see that each 
partition has specific top terms and top assignees. Furthermore, there is a link between the top terms and the 
top assignees. For instance, partition N1 contains keywords that are related to optics applied to networking 
while the top assignees are firms that networking solutions companies. Top terms in Partition N3 are related 
to nanomedicine and the main assignees are pharmaceuticals or universities. From this perspective, 
modularity optimization partitioning of patent citation networks seems to be an effective way of delineating 
technological fields of expertise. Another aspect for evaluating the partitioning is the distribution of patents 
for assignees within partitions. Regarding this issue, we further analyze partitions N2 and N4.  These 
partitions are all dominated by one company: Xerox Corporation. Examining these partitions one at a time 
might be an indication that the partitioning is only grouping patents from the same company. However, a 
closer look at the top keywords for each one indicates that these are three different types of technologies 
related to printing solutions: N2 and N4 contain applications for laser and inkjet printers respectively. 
Therefore, the modularity-based partitioning of patent citation networks seems also effective in delineating 
different fields of expertise possessed by a very large company such as Xerox Corporation. It should be noted 
that the domination of printing technologies clusters by Xerox is natural given the fact that our sample 
contains Canadian-made patents only. Therefore, other large producers of printing technologies which are 
not present in Canada are not represented here.  
By examining partition N2, we find that the last three assignees aren’t printing technology companies. This is 
due to the fact that these patents are linked to similar technologies than printing patents and that their 
assignment to partition N2 gives result to better network modularity. Such cases represent a small proportion 
of patents and will not have significant impact on the aggregate results. Indeed, the top 4 disciplines in Table 
3 contain more than 958 patents, with only 3 of them that are falsely assigned. 
Table 3: Top 10 terms and top 5 assignees for the 5 largest partitions in the Canadian nanotechnology network 
Partition ID Top 10 Terms Top 5 Assignees (% of patents in partition) 
N1 optical 
grating 
waveguide 
fiber 
signal 
compensation 
dispersion 
bragg 
polarization 
wavelength 
Nortel Networks (28.3) 
JDS Uniphase Corporation (4.6) 
Teraxion Inc. (4.2) 
Institut National d'Optique (3.3) 
Her Majesty the Queen in Right of Canada (2.9) 
 
N2 toner Xerox Corporation (97.5) 
 
 
14 
latex 
resin 
particles 
surfactant 
pigment 
emulsion 
toner particles 
colorant 
ionic surfactant 
Palo Alto Research Center, Inc. (0.7) 
Angiotech Pharmaceuticals (0.4) 
Ballard Power Systems Inc. (0.4) 
Ocean Nutrition Canada Limited (0.4) 
 
N3 lipid 
liposomes 
liposome 
liposomal 
drug 
lipids 
vesicles 
nucleic 
therapeutic 
lipid-nucleic 
Inex Pharmaceuticals Corp. (11.2) 
The Liposome Company, Inc. (9.8) 
University of British Columbia (8.8) 
RTP Pharma Inc. (2.9) 
McGill University (2.4) 
 
N4 phthalocyanine 
photoconductive 
charge transport 
photoconductive imaging 
photogenerating 
charge transport layer 
photogenerating layer 
transport layer 
charge 
titanyl 
Xerox Corporation (98.2) 
Fuji Xerox Co., Ltd. (1.2) 
Group IV Semiconductor Inc. (0.6) 
University of Rochester (0.6) 
 
It is also worthwhile noticing that top terms extracted from the titles and abstracts of patents in the 4 largest 
nanotechnology partitions are different from those that were initially chosen for patent extraction from the 
USPTO database (see Table 1). This finding seems to indicate that the world of technology is developing its 
own technical corpus to describe the inventions that it is developing. Of course, the fact that these 
documents were extracted with the use of keywords originating from the world of science is an indication 
that there is knowledge flows from the world of science to the world of technology. However, once basic 
concepts are transferred to the world of technology, they are transformed into applications which are 
described with brand new expressions. This finding can point in favor of citation-based query expansion 
methods (Zitt and Bassecoulard, 2006) to complement lexical document extractions. Indeed, patents that 
don’t link to terms from the scientific literature will be missed if the extraction process is limited to lexical 
extractions. This is even more important for mature fields that are relying increasingly on technology and 
decreasingly on science. 
By examining the top keywords and assignees for the 103 nanotechnology partitions, we have identified 46 
partitions related to nanomedicine. Altogether, these partitions cover 1,479 patents which represent an 
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average annual production of nearly 80 patents for the period 1990 to 2009. The second partitioning of this 
smaller network finds 38 distinct fields of expertise. Table 4 shows the six largest nanomedicine domains 
identified from the sample of nanomedicine patents. These partitions group patents that have applications 
mainly in Liposomal formulations, cancer treatment and regenerative medicine. Our results coincide with the 
nanomedicine report by the ESF (2005, p. 43) where liposomal formulations (Doxil®/Caelyx® and 
Ambisome®) are said to have reached the market stage and generated considerable sales ($300M and $100M 
respectively for the two drugs) in 2004. Given the very competitive nature of the pharmaceuticals industry, 
the profits associated with gaining market share and the fact that patents in this industry are usually of better 
value, we can conclude that the domain of liposomal formulation offers the best opportunities in terms of 
commercial potential. The other major disciplines are also of comparable size relative to the latter discipline, 
which could mean that they also have commercial potential. Trends analysis for other patent quality metrics 
will add to this perspective. 
Table 4: Six largest fields of expertise in nanomedicine. 
Technological field Size 
Liposomal Formulation 187 
Therapeutics (Alzheimer) 138 
Tumor Suppression (Reovirus) 118 
Tissue Engineering 112 
Therapeutics (Stem Cells) 110 
Cancer Treatment (Telomerase) 104 
6.2 Industry assessment 
Figure 3 shows the cumulative number of patents produced in nanomedicine by Canadian inventors from 
1990 to 2009. As we can see, patent production is on the rise. It is however difficult to tell in which stage of 
the S-shaped growth the field is from this graph. Figure 3 also shows the evolution of patent metrics over the 
years. As we can see, there was a slowdown in terms of patent production between years 1999 to 2005 with a 
second wave of rise between 2005 and 2007. Furthermore, trends in the average number of NPRs seem to 
indicate two cycles that are aligned with patenting rises and slowdowns. 
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Figure 3: Nanomedicine patent metrics trends (all sub-disciplines included). 
The first slowdown period (1999 to 2005) is also marked by a slowdown in the number of NPRs. Again, the 
2005-2007 rises in patenting are also accompanied with a rise in the average number of NPRs. This is a very 
interesting finding regarding the science-technology relationship in nanomedicine. During slowdowns, new 
patents seem to involve incremental technological improvements. Once technological opportunities are 
exhausted, communities of practice tend to source their knowledge from basic science which leads to another 
growth cycle in patenting. The number of backward citations is clearly improving over the years, but also 
follows a trend that is relatively parallel to that of granted patents. Here, the average number of backward 
citations seems to depend upon the available technologies. As patent production rises, the technological base 
on which new patents rely also seems to rise. Concerning the 2008-2009 slowdowns in the number of granted 
patents, we observe that it is accompanied by rises in both NPRs and backward citations. This could indicate 
that a third wave of development attracting greater resources is on its way, but that the field is increasingly 
linked to the technology world even if it still relies on basic science. The evolution of the number of claims is 
stable over time. Considering the number of forward citations after 7 years of a patent’s grant date, we do not 
notice any clear rise. This seems to indicate that nanomedicine is still linked to other technological fields. 
Indeed, if nanomedicine patents where increasingly relying on nanomedicine patents, we would see a rise in 
forward citation similar to that of backward citations. These figures seem to indicate that, although getting 
closer to commercialization, the Canadian nanomedicine industry is still far from reaching its maturity. 
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Figure 4 shows patent metrics for the largest nanomedicine subfields. Patent production is on the upside for 
most of the fields of expertise except for liposomal formulation and tumor suppression which seems to have 
slowed down. For liposomal formulation, there is a trending rise in NPRs and backward citations. This could 
indicate that the field might be going through an exploitative cycle where reliance upon technology is 
growing. The same observations can be made for tumor suppression applications. Since the number of 
backward citations and NPRs are stable, and that first patents have appeared in 1995, this field seems to be 
relatively young. The initial rapid growth of the field is thus an indication of higher perceived technological 
opportunities, with a period of knowledge resourcing that could be ahead. None of the other top fields 
however shows any sign in reaching its S-shaped growth inflection point. 
 
Figure 4: Trend analysis for top nanomedicine sub-disciplines. Definition of disciplines for legend: 1) Liposomal 
Formulation, 2) Stem Cells, 3) Alzheimer, 4) Telomerase, 5) Tumor Suppression and 6) Tissue Engineering. 
The average number of backward citations and NPRs are also generally on the rise. This is an indication that 
major fields of expertise are increasingly linking with both the technology and science world. This is especially 
true for Telomerase applications which are increasingly linked to technology and science bases. We therefore 
expect to witness future cycles of growth in this field. Concerning the number of claims, figures show stability 
over the years. Finally, forward citations trends seem mostly on the downfall. This could be an indication that 
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Canadian patents in nanomedicine are generally failing to lead to subsequent developments from within the 
industry. These trends seem to point out that Canadian nanomedicine patents have quite some development 
ahead before commercialization. Although patent quality is improving within the sector, it still links heavily 
with technologies from other disciplines. Even if we observe rises in forward citations in certain areas, they 
are temporary as dominant designs do not seem to emerge from within the industry.
Figure 5 shows the map of Canadian fields of expertise in nanomedicine. Force-directed placement assigns 
coordinates to patents that cite the same sources in the same region of the graph. Vertex size represents the 
number of patents produced in that field of expertise and edge size represents the number of citations that 
the two fields have in common. As the graph shows, nanomedicine fields of expertise are highly interrelated. 
Indeed, our map of major nanomedicine fields of expertise is closer a complete graph rather than a small-
world. This seems to indicate that these fields are related to a common set of technologies. 
Figure 5: Knowledge map of Canadian nanomedicine fields of expertise.
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As we can see in Table 5, Vancouver, Toronto and Montreal are the main centers for nanomedicine 
technology development. However, for a country that covers a very large geographical area, it is worthwhile 
observing that the majority of Canadian nanomedicine inventors reside on the south-eastern region of the 
country. This is somehow representative of the distribution of the general population in the Country. It 
should also be observed that some cities have a higher concentration of nanomedicine inventors. In this 
regard, Vancouver and Quebec City are the leading regions in terms of the clustering of nanomedicine 
communities of practice.  
The Herfindahl index in Table 5 shows to what degree innovative activity is diversified within cities. This 
measures how uniformly patents produced by inventors residing in the city are distributed among the 
disciplines. Since our analysis covers 38 fields of expertise, a perfectly diversified city (one that produces the 
same number of patents in each of the 38 disciplines) will have a Herfindahl index of 0.026. As we can see 
from the results, cities are more or less diversified at the same level. Diversification is generally associated 
with city and community of practice size as we can see for Montreal and Toronto. Vancouver seems to be an 
outlier however as it has both the largest community and the highest level of technological concentration. 
Table 5: Nanomedicine inventors as a percentage of total population in the largest nanomedicine metropolitan areas 
 Edmonton Montreal Ottawa Quebec Toronto Vancouver 
Population 1,159,869 3,824,221 1,236,324 765,706 5,583,064 2,313,328 
Number of nanomedicine 
inventors 
82 255 74 77 276 289 
Proportion (per thousand 
inhabitants) 
0.071 0.067 0.061 0.097 0.049 0.125 
Herfinahl Index 0.1071 0.0764 0.134 0.164 0.080 0.1492 
 
Table 6 shows how expertise in the largest nanomedicine fields is distributed within Canadian cities. Here, the 
Herfindahl index indicates the level with which patent production in a field of expertise is distributed among 
Canadian cities. Given the fact that we study 6 cities, a field of expertise for which an equal number of 
patents are produced in each city will have and index of one sixth. As we can see, the development of 
application related to stem-cell-based therapeutics is more equitably spread within major Canadian cities. 
However, the major field of expertise (Liposomal formulation) is mostly concentrated in Vancouver. Given 
the size of the discipline and the fact that it is the most market-ready solution in nanomedicine, the above 
results mark the importance of Vancouver as a center for nanomedicine development. The emergence of 
Vancouver as a pole for innovative activity in nanomedicine is a sign that the industry is gaining traction. 
However, activities have not clustered in Vancouver to a degree where it shadows other leading cities.  
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Table 6: Concentration of production for major nanomedicine fields of expertise 
 Liposomal 
Formulation 
Therapeutics 
(Alzheimer) 
Tumor 
Suppression 
(Reovirus) 
Tissue 
Engineering 
Therapeutics 
(Stem Cells) 
Cancer 
Treatment 
(Telomerase) 
Edmonton 0.0803 0.0147 0.1028 0.0795 0.0568 0.0105 
Montreal 0.1387 0.2941 0.1495 0.1364 0.3864 0.1789 
Ottawa 0.0146 0.0294 0.0187 0.0341 0.1136 0.0632 
Quebec 0.0657 0.0000 0.0467 0.1250 0.0795 0.1263 
Toronto 0.1168 0.4118 0.2897 0.5227 0.1818 0.3684 
Vancouver 0.5839 0.2500 0.3925 0.1023 0.1818 0.2526 
Herfindahl 
index 
0.3848 0.3196 0.2735 0.3254 0.2379 0.2516 
 
From the 38 fields of expertise discovered, we can identify 586 distinct organizations. The Herfindahl index 
taking the share of patents that each firm owns is equal to 0.01, indicating that the industry is very 
competitive in the sense that there isn’t one single firm that produces most of the innovations. Table 7 shows 
the top 20 organizations in terms of patent production. Endorecherche, Inc. (Quebec City) is the largest private 
patent holder headquartered in Canada with only 2.16% of the patents in the sector. Other top organizations 
share a very small fraction of patents in the industry. This very competitive nature of nanomedicine also 
seems to point at the distance that it has to commercialization. 
As we can further see in Table 7, public institutions play an important role in the production of patents. 
Indeed, four out of the top five patent holders in nanomedicine are public institutions. This can once again be 
explained by the fact that nanotechnology is an emerging multidisciplinary field where science linkage is a 
dominant pattern in inventions. Being the generators of basic knowledge, public institutions are closer to 
science and have access to broad set of expertise. As the nanotechnology sector matures, we can expect larger 
private firms, similar to Nortel and Xerox in their respective sectors, to have a more dominant role in patent 
production as inventions will rely less on basic science and as private firms will have access to more 
resources. 
Table 7: Top 20 organizations in terms of the number of patents produced 
Organization Number of patents Share of patents produced (%) 
University of British Columbia 58 3.92 
National Research Council of Canada 39 2.64 
Queen's University  39 2.64 
Hyal Pharmaceutical*** 38 2.57 
McGill University 36 2.43 
Endorecherche* (Quebec City) 32 2.16 
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Inex Pharmaceuticals* (Vancouver) 24 1.62 
Adherex Technologies 22 1.49 
Geron Corporation 22 1.49 
Generex Pharmaceuticals* (Toronto) 20 1.35 
The Liposome Company 20 1.35 
Arius Research*** 17 1.15 
Nucryst Pharmaceuticals** (Toronto) 16 1.08 
NeuroSpheres Holdings* (Calgary) 15 1.01 
Aegera Therapeutics* (Montreal) 14 0.95 
LAM Pharmaceuticals* (Toronto) 14 0.95 
Oncolytics Biotech* 14 0.95 
Supratek Pharma* (Montreal) 14 0.95 
QLT 13 0.88 
University of Alberta 12 0.81 
All Others 948 67.71 
Notes: * indicates active firm headquartered in Canada; ** indicate firms acquired by Canadian firm; *** 
indicate firms acquired by non-Canadian firm 
Figure 7 shows technological proximity between inventing organizations. Again, the size of the vertex is an 
indication of the number of nanomedicine patents produced by the organization and the size of edge 
represents the number of common citation that patents from two organizations have in common. We can 
notice the central role of the University of British Colombia (UBC) as well as other universities and public 
institutions. As it is characteristic of the early stages of an industry, universities play a gatekeeping role that 
binds private firms together (Owen-Smith and Powell 2004). Indeed, geographical and technological 
proximity to the UBC seems to coincide with the dominant position that Inex Pharmaceuticals plays in the 
liposomal formulation industry.  
22 
Figure 6: Map of the most innovative nanomedicine organizations. 
7! Conclusion 
In this article, our main objective was to develop a method to discover and map fields of expertise in an 
emerging industry. Our method was based on the  greedy modularity optimization of patent backward 
citation networks. As a case study, we have selected Canada’s nanomedicine industry. With regards to the 
self-organizing nature of technological development by communities of practice, our method promises clear 
advantages over US-class-based patent mapping techniques. First, US class 977 is currently assigned to only 
156 Canadian patents granted between years 1990 to 2005. This represents a mere 2% of the 6,288 identified 
by our extraction method. Second, since class assignment and citations are somehow related, our method 
does not give results that are contradictory to class-based patent mapping methods. Instead, it takes into 
account the complexity of technological interrelatedness between patents. It thus is a more refined 
representation of intellectual organization.   
From a methodological point of view, our results support the relevance of patent citations as a way to 
measure technological proximity between inventions. First, graphs resulting from co-citations exhibit small-
world and scale free characteristics common to many real-world networks. Second, we observe that 
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modularity optimization of patent citation networks allows for discerning the subtle differences between 
fields of expertise in a multidisciplinary industry. Third, patent citations are also detailed enough to 
distinguish between different fields of expertise for very large organizations such as Xerox Corporation. Fourth, 
the major field of expertise identified by partitioning the Canadian nanomedicine co-citation network is 
liposomal formulation, a field that has shown market readiness in other countries. Whether added by 
examiners or applicants, patent citations do not appear to be the result of an arbitrary and noise-adding 
process. Citation-based unsupervised learning techniques allows us to obtain refined knowledge about the 
application domains within an emerging industry in which continuous development are ultimately defined by 
the collective effort of the communities of practice and for which standard classification is yet incomplete. 
We have identified 6 major fields of expertise in nanomedicine. The central theme of innovative development 
appears to be around drug delivery applied to cancer treatment. To the 6 major fields of expertise, we have 
applied a multi-metric approach for assessing their development stages. Generally speaking we cannot 
conclude that Canadian nanomedicine fields of expertise are ready for commercialization purposes. By 
performing multi-metric trends analysis, we observe that not all fields are at the same stage of development. 
Comparisons between trends in NPRs forward and backward citations show that nanomedicine still sources 
itself in basic science as well as other technological sectors and disciplines. Also, the progress of these metrics 
does not seem to follow a pattern that could clearly indicate the leap of one discipline from other disciplines. 
Rather, each discipline is making progress of different nature, without one making progress in all metrics.  
We have also identified leading Canadian organizations developing technologies applied to nanomedicine. 
Our results show that this sector is very competitive and that landscape is still many years away from the 
emergence of dominant private firms. The absence of dominant players further hints at the embryonic stage 
of this field. Whether large nanomedicine corporations will emerge, or whether smaller ones will be merged 
to large pharmaceutical companies who will become main producers seems to be still many years away. We 
have also observed that public institutions play an important role in patent production as well as bridging 
different technological fields together. Canadian public institutions, and especially universities, represent 4 out 
of the top 5 producers of intellectual property in nanomedicine. This is much higher than what is reported by 
studies about nanotechnology as a whole, where one or two out of top 5 leading organizations where public 
institutions. Among them, the UBC plays the most central role within the nanomedicine industry. This 
finding is aligned with those concerning the birth of the biotechnology industry in Boston (Owen-Smith and 
Powell 2004). Canadian universities are both large as well as central players on the nanomedicine front line. 
They also play an important role as sources of knowledge when technological opportunities stagnate. 
Furthermore, although our city-level analysis seems to point to the dominance of Vancouver as an attractive 
location for further expansions of innovative capabilities in nanomedicine, the geographic agglomaration of 
inventive activities is not strictly limited to this metropolitan area. Other cities such as Toronto and Montreal 
are leaders in tissue engineering and stem cells technology respectively. In this regard, the presence of McGill 
University as both a top patent holder and a central player in the assignee network seems to indicate 
agglomeration trends in Montreal. Such conclusions about the stage of development of an emerging industry 
cannot be made by relying solely on patent counts. These observations thus show that following trends in 
multiple indicators offers new insights for forecasting future development in an industry. 
A first limitation of our research lies in the difficulty of assigning central patents to a community. The 
adoption of overlapping community detection or multiresolution modularity optimization techniques can 
help overcome this issue. Another limitation in our method resides in the classification of clusters based on 
expert search. Although cluster labels are obtained based on the relevance of keywords from patent titles and 
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abstracts, they are subjectively contextualized by the expert. Depending on the knowledge background of the 
expert, different classifications can be given to the same cluster. Ontology libraries can help overcome this 
limitation and constitute the second potential improvement to our method. However, this is a challenging 
task given the fast evolving nature of technical terms in highly innovative sectors. Finally, the regulatory 
aspect of nanomedicine commercialization means that there is a lag between when technological 
developments flourish and when they can reach acceptance for market deployment. Using bibliometric data 
that solely reflects technological development cannot be used as an absolute metric for market readiness. 
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